Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

50.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,691
Open 50.86
Bid (Size) 51.39 (15)
Ask (Size) 51.43 (10)
Prev. Close 50.86
Today's Range 50.86 - 50.86
52wk Range 45.80 - 60.12
Shares Outstanding 1,250,690,553
Dividend Yield 4.01%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors. 
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga

Performance

YTD
+5.5%
+5.5%
1 Month
+0.5%
+0.5%
3 Month
-5.8%
-5.8%
6 Month
+6.4%
+6.4%
1 Year
+3.8%
+3.8%

More News

Read More
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
Earnings Scheduled For April 24, 2025
Via Benzinga
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
Via Benzinga
Exposures COVID-19
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
Via Benzinga
SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
Via Benzinga
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Via Investor's Business Daily
Topics Earnings Government
Exposures Financial Political
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.
Via Chartmill
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
Via Benzinga
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
Via Benzinga
How Do Investors Really Feel About Sanofi?
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?
Via The Motley Fool
Topics Economy Government World Trade
Exposures COVID-19 Economy Political
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
Via Investor's Business Daily
FDA Approves Sanofi's Hemophilia Drug
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 50.86
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 05/15/25 04:00 PM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 63.61B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 64B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.